Join Free For Buyer|Sign In

Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and Equipment_EN-CPhI.cn

You are here:  Home >>  News >>  Editors’ Picks >>  Changes of the Global HIV Drug Market in 10 Years

Changes of the Global HIV Drug Market in 10 Years

September 30, 2018 By 1℃
Tag: GSK , gilead , AIDS , HIV drugs

AIDS is becoming a chronic disease. According to data, size of the global HIV drug market approached USD 23.5 billion in 2017. Gilead dominates the global HIV drug market: it occupied more than half of the relevant global market share according to 2017 data, and its triple/quadruple regimen of 2NRTI+INSTI/NNRTI based on TAF is becoming the mainstream regimen of the HIV drug market. Here, I analyze and organize the 10-year market data of main HIV drugs on the global market, and give an overview of the global HIV drug market from the perspective of company, product, and drug combination regimen.

Changes of the Global HIV Drug Market in 10 Years

I. Global market share reached USD 23.3 billion, with Gilead dominating the HIV drug market

Gilead, GSK, BMS, and MSD are the leading companies on global HIV drug market, especially, Gilead: it alone occupied 51% share of the global HIV drug market (the statistical data below include its HBV drug sales). With the declining of its HCV DAA business, Gilead’s HIV drug business continues to rapidly grow, especially, the success of the new-generation HIV drugs based on TAF have brought a new growth point to Gilead, and led to the most brilliant financial report data of Gilead (see Gilead Released 2017 Financial Report: HCV Drug Business Continued to Slump while the New-generation HIV Drug Products Surged by 184% for the details).

Sales of Major Companies on the Global HIV Drug Market from 2008 to 2017

2008-2017年全球艾滋病市场主要公司销售额

(百万,美金)

Sales of Major Companies on the Global HIV Drug Market from 2008 to 2017

(USD 1 million)

II. The quadruple regimen Genvoya fast growing into a star of today

The success of the cocktail therapy has brought breakthroughs to AIDS control. The STRs (single-tablet regimens) have significantly prolonged patients’ lifetime, and their market share is rapidly expanding. STRs accounted for 72% share of global HIV drug market by 2017, and this figure will continue to increase.

Market Shares of Single Drugs vs STRs

单方 VS STR市场份额%

单方

Market Shares of Single Drugs vs STRs

Single drugs

From the perspective of single product: the quadruple regimen Genvoya becoming the star of today, with 2017 sales reaching USD 3.7 billion

Sales of Major Products on the Global HIV Drug Market from 2008 to 2017

2008-2017年全球艾滋病市场主要产品销售额

(百万,美金)

Sales of Major Products on the Global HIV Drug Market from 2008 to 2017

(USD 1 million)

From the perspective of category, HIV drugs are mainly divided into nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs), and protease inhibitors (PIs), etc., and the cocktail therapies that combine 2NRTI and other antivirals are currently the most successful AIDS control regimen.

Genvoya is a new quadruple regimen, with 2NRTI+INSTI+PK enhancer. Its sales have been advancing rapidly since approved at the beginning of 2015, and it has now become the top 1 on the HIV drug market.

 

2NRTI+INSTI based on TAF being the most successful cocktail therapy so far

Market Shares of Mainstream Regimens on Global HIV Drug Market from 2008 to 2017

2008-2017年全球艾滋病市场主流方案市场份额

Market Shares of Mainstream Regimens on Global HIV Drug Market from 2008 to 2017

It’s clear from the above figure that among the STRs, 2NRTI and 2NRTI+NNRTI regimens have become stable and been declining, while the triple/quadruple regimens based on 2NRTI+INSTI are gradually expanding and becoming the most important AIDS control regimens at present.

Here I list several noteworthy drugs in detail in the following table, so as to show the future development trends of HIV drug combination regimens more clearly:

Year

Trade name

Generic name

Drug regimen

Growth expectation

2017 sales, USD 1 million

Company

2015

Genvoya

cobicistat; elvitegravir; emtricitabine; TAF

2NRTI+INSTI+PK enhancer

+++++

3674

Gilead

2014

Triumeq

abacavir; dolutegravir; lamivudine

2NRTI+INSTI

+++

3171.3

GSK

2004

Truvada

emtricitabine; TDF

2NRTI

--

3134

Gilead

2006

Atripla

efavirenz; emtricitabine; TDF

2NRTI+NNRTI

---

1806

Gilead

2016

Descovy

emtricitabine; TAF

2NRTI

+++++

1218

Gilead

2016

Odefsey

emtricitabine; rilpivirine; TAF

2NRTI+NNRTI

+++++

1106

Gilead

2012

Stribild

cobicistat; elvitegravir; emtricitabine; TDF

2NRTI+INSTI+PK enhancer

---

1053

Gilead

2011

Complera

emtricitabine; rilpivirine hydrochloride; TDF

2NRTI+NNRTI

---

966

Gilead

2000

Kaletra

lopinavir; ritonavir

PI+PK enhancer

---

423

AbbVie

2004

Epzicom

abacavir; lamivudine

2NRTI

----

301.5

GSK

2017

Juluca

dolutegravir; rilpivirine

NNRTI+INSTI

+++++

6.4

GSK

 

 

 

 

 

 

 

Sales in the table have been converted into USD at average exchange rate

+: Positive sales expectation

-: Negative sales expectation

The table shows more clearly the future development trends of HIV drug combination regimens:

1. The market share of the triple/quadruple regimens based on 2NRTI+INSTI will continue to rise;

2. The new-generation HIV drugs developed based on TAF represented by Genvoya, Odefsey, and Descovy will enjoy increased sales in the future and gradually substitute TDF.

AIDS will be eliminated one day, sooner or later, as the global pharmaceutical industry progresses. The current mainstream regimens have been able to control AIDS. Which will be the breakthrough point for the functional cure of AIDS in the future? Vaccine, antibody, gene therapy, or immunotherapy? I don’t know, however, what I do know is that AIDS will be ended one day.

-----------------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

 

Readers'Comments
Add a comment
Click here to Login or to Register for free. You will be taken back to your selected item after Login/Registration.
More>> MarketNews
More>> Editors’Picks
More>> TopStories
More>> HotTags
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53
网页对话
live chat